CN105272920B - Bendamustine hydrochloride mannitol ester and preparation method and application thereof - Google Patents
Bendamustine hydrochloride mannitol ester and preparation method and application thereof Download PDFInfo
- Publication number
- CN105272920B CN105272920B CN201410341785.9A CN201410341785A CN105272920B CN 105272920 B CN105272920 B CN 105272920B CN 201410341785 A CN201410341785 A CN 201410341785A CN 105272920 B CN105272920 B CN 105272920B
- Authority
- CN
- China
- Prior art keywords
- bendamustine hydrochloride
- hydrochloric acid
- formula
- preparation
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960001215 bendamustine hydrochloride Drugs 0.000 title claims abstract description 47
- 229930195725 Mannitol Natural products 0.000 title claims abstract description 23
- 239000000594 mannitol Substances 0.000 title claims abstract description 23
- 235000010355 mannitol Nutrition 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- -1 Bendamustine hydrochloride mannitol ester Chemical class 0.000 title abstract description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 44
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 claims abstract description 35
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims abstract description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 238000004440 column chromatography Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 4
- 239000012295 chemical reaction liquid Substances 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims 1
- 239000012535 impurity Substances 0.000 abstract description 9
- 238000002347 injection Methods 0.000 abstract description 8
- 239000007924 injection Substances 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 5
- 239000013558 reference substance Substances 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000011821 Indolent B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410341785.9A CN105272920B (en) | 2014-07-17 | 2014-07-17 | Bendamustine hydrochloride mannitol ester and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410341785.9A CN105272920B (en) | 2014-07-17 | 2014-07-17 | Bendamustine hydrochloride mannitol ester and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105272920A CN105272920A (en) | 2016-01-27 |
CN105272920B true CN105272920B (en) | 2020-01-24 |
Family
ID=55142820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410341785.9A Active CN105272920B (en) | 2014-07-17 | 2014-07-17 | Bendamustine hydrochloride mannitol ester and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105272920B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101119708A (en) * | 2005-01-14 | 2008-02-06 | 赛福伦公司 | Bendamustine pharmaceutical compositions |
CN103351347A (en) * | 2013-07-29 | 2013-10-16 | 东南大学 | Preparation method of impurity DCE in bendamustine hydrochloride |
-
2014
- 2014-07-17 CN CN201410341785.9A patent/CN105272920B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101119708A (en) * | 2005-01-14 | 2008-02-06 | 赛福伦公司 | Bendamustine pharmaceutical compositions |
CN103351347A (en) * | 2013-07-29 | 2013-10-16 | 东南大学 | Preparation method of impurity DCE in bendamustine hydrochloride |
Non-Patent Citations (2)
Title |
---|
Development and validation of RP-HPLC method for determination of related substances of bendamustine hydrochloride in bulk drug;E. Sasi Kiran Goud,等;《Der Pharmacia Sinica》;20131231;第4卷(第1期);29-36 * |
Stability-Indicating LC Method for the Estimation of Bendamustine Hydrochloride and its Related Impurities;Srinivasulu Kasa,等;《Journal of Chromatographic Science》;20141231;第52卷;573-583 * |
Also Published As
Publication number | Publication date |
---|---|
CN105272920A (en) | 2016-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2602968C (en) | Crystals of morphinan derivative and process for producing the same | |
EP2955186A1 (en) | Process for purifying staurosporine | |
CN101863948B (en) | High-purity (2 beta, 3 alpha, 5 alpha, 16 beta, 17 beta)-2-(4-morpholinyl)-16-(1-pyrrolidinyl)-androstane-3,17-diol or composition thereof and preparation method thereof | |
Gao et al. | Radiosynthesis of [11C] Vandetanib and [11C] chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer | |
CN107325082B (en) | Preparation method of high-purity afatinib | |
CN105272920B (en) | Bendamustine hydrochloride mannitol ester and preparation method and application thereof | |
CN107513053A (en) | A kind of preparation method of sitafloxacin hydrate | |
CN104402758B (en) | A kind of preparation method of iohexol impurity | |
CN109134331B (en) | Synthesis method of azithromycin genotoxic impurity | |
CN112979552A (en) | Preparation method of high-purity dexmedetomidine hydrochloride | |
CN106748961A (en) | The impurity compound of Nintedanib, preparation method, using and its detection method | |
CN102775424A (en) | Preparation method for levofloxacin impurity | |
CN105330664B (en) | A kind of synthetic method of Xi Gelieting impurity | |
CN106316953A (en) | Synthetic method of 6-cyanophenanthridine compounds | |
WO2016014864A1 (en) | Hydroxy-(r)-2,2'-bismethylnal trexones and uses thereof | |
CN111892533B (en) | Regorafenib related substance, and preparation method and application thereof | |
CN104109135A (en) | Preparation method of 1-[2-(2,4-dimethyl phenylsulfanyl)-phenyl]piperazine | |
CN104072491A (en) | Azilsartan derivative compound and preparation method and application thereof | |
CN103739635B (en) | A kind of purification process of mannose triflate intermediate | |
CN1023121C (en) | Crystal of hydrochloric salt of etoposide-2-dimethylamino compounds and process for preparing them | |
CN104334561B (en) | compound JK12A and preparation thereof | |
CN106946959B (en) | Synthesis of related substances of 5,6, 4' -trihydroxyflavone-7-0-D-glucuronic acid and preparation method and application thereof | |
CN104945398B (en) | A kind of moxifloxacin impurity E preparation method | |
CN105566296A (en) | Method for preparing dabigatran amidated impurities | |
CN104450851B (en) | A kind of preparation method for removing acetyl cefathiamidine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Liandi Inventor after: Liao Mingyi Inventor after: Yang Shaoning Inventor after: Ding Lei Inventor after: Li Xiaoqiang Inventor after: Ren Jinsheng Inventor before: Zhang Liandi Inventor before: Liao Mingyi Inventor before: Yang Shaoning Inventor before: Ding Lei Inventor before: Li Xiaoqiang |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230616 Address after: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311 Patentee after: Xiansheng Zaiming Pharmaceutical Co.,Ltd. Address before: 210042 699 Xuanwu Road, Xuanwu District, Nanjing, Jiangsu -18 Patentee before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311 Patentee after: Hainan Xiansheng Zaiming Pharmaceutical Co.,Ltd. Country or region after: China Address before: No. 20 Yaogu Yiheng Road, Xiuying District, Haikou City, Hainan Province, 570311 Patentee before: Xiansheng Zaiming Pharmaceutical Co.,Ltd. Country or region before: China |
|
CP03 | Change of name, title or address |